| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8707319 | Oral Oncology | 2018 | 6 Pages |
Abstract
When treating p16+ OPC with CRT, the threshold for substitution of cisplatin with cetuximab should be maintained appropriately high in order to prolong survival times and optimize locoregional and distant tumor control. When cetuximab is used in cisplatin-ineligible patients, altered fractionation RT should be considered in an effort to improve LRC.
Keywords
p16 proteinRFSCrtOPCLRCRPADMFSRecurrence-free survivaloverall survivalrecursive partitioning analysisDose fractionationRadiotherapyCetuximabOropharyngeal cancerHead and neck cancercisplatinChemoradiotherapyOropharyngeal neoplasmsHuman papillomavirusOropharyngeal carcinomachemoradiationLocoregional control
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Christian L. Barney, Steve Walston, Pedro Zamora, Erin H. Healy, Nicole Nolan, Virginia M. Diavolitsis, Anterpreet Neki, Robert Rupert, Panos Savvides, Amit Agrawal, Matthew Old, Enver Ozer, Ricardo Carrau, Stephen Kang, James Rocco, Theodoros Teknos,